Saudi Arabia Next Generation Sequencing (NGS) Market (2024-2031)
The Saudi Arabia NGS Market was valued at $ 24.4 million in 2023. This market is anticipated to reach $50 million by 2031 from an estimated $ 25.5 million in 2024, at a CAGR of 10.1% during the forecast period from 2024 to 2031. Saudi Arabia NGS Market Size & Forecast
- Published
- Sep 2024
- Pages
- 183
- Format
- PDF + Excel
- Report ID
- MRHC - 1041319
- Base year
- 2023
- 2023 · BASELINE
- $24.4M
- 2031
- $50.0M
- CAGR 2024–2031
- 10.1%
2023 baseline · 2024–2031 forecast at 10.1% CAGR · hover a bar for the value
Key highlights
The Saudi Arabia NGS Market was valued at $ 24.4 million in 2023.
This market is anticipated to reach $50 million by 2031 from an estimated $ 25.5 million in 2024, at a CAGR of 10.1% during the forecast period from 2024 to 2031.
The Consumables Segment to Dominate the Market
The targeted genome sequencing segment is expected to account for the largest share of the Saudi Arabia NGS market.
The Research Applications Segment to Dominate the Market
Report summary
| Particulars | Details |
|---|---|
| Number of Pages | 183 |
| Format | |
| Forecast Period | 2024–2031 |
| Base Year | 2023 |
| CAGR (Value) | 10.1% |
| Market Size (Value) | USD 50.0 million by 2031 |
| Segments Covered | Saudi Arabia NGS Market, by Offering · Consumables · Sample Preparation Consumables · Library Preparation & Target Enrichment · DNA Extraction and Amplification · Quality Control · Other Kits & Reagents · Sequencing Consumables · NGS Platform/Instruments · Sequencing by Synthesis · Ion Semiconductor Sequencing · DNA Nanoball (DNB) Sequencing · Single-molecule Real-time Sequencing & Nanopore Sequencing · Software · Services · (Note: Other kits & reagents include dilution buffers, DNA standards, reagents for DNA cleanup and nucleic acid extraction, and other reagents required to support the NGS sample preparation workflow.) · Saudi Arabia NGS Market, by Sequencing Type · Targeted Genome Sequencing · Whole Genome Sequencing · Whole Exome Sequencing · Other Sequencing Types · (Note: The other sequencing types segment include degradome sequencing, chromatin immunoprecipitation (ChIP) sequencing, and methylation sequencing.) · Saudi Arabia NGS Market, by Application · Research & Other Applications · Cancer Research · Agriculture & Animal Research · Microbiology & Infectious Disease Research · Genetic Diseases Research · Cell & Molecular Biology Research · Other Applications · Clinical Applications · Oncology · Reproductive Health · Infectious Disease · Genetic Disorders · Other Clinical Applications · (Note 1 : Other applications include food microbiology, microbiome analysis in the beverage industry, and environmental studies) · (Note 2 : Other clinical applications include the detection of metabolic and immune disorders and foodborne illnesses.) · . Saudi Arabia NGS Market, by End User · Pharmaceutical & Biotechnology Companies · Hospitals & Diagnostic Laboratories · Academic Institutes & Research Centers · Other End Users · (Note: Other end users include forensic laboratories & security agencies, food & beverage companies, and agriculture companies.) |
| Countries Covered | Saudi Arabia |
| Key Companies | Some of the key players operating in Saudi Arabia NGS market are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Revvity, Inc. (U.S.), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), Pacific Biosciences of California, Inc. (U.S.), Danaher Corporation (U.S.), Oxford Nanopore Technologies Plc. (U.K.), Beijing Genomics Institute (BGI) (China), Bio-Rad Laboratories, Inc. (U.S.), and 10x Genomics, Inc. (U.S.). |
Report overview
Segments covered: offering, consumable, sample preparation consumable, library preparation & target enrichment, dna extraction, amplification, quality control, other kits & reagent, sequencing consumable, ngs platform/instrument, sequencing by synthesis, ion semiconductor sequencing, software, service, sequencing type, targeted genome sequencing, whole genome sequencing, whole exome sequencing, other sequencing type, application, research & other application, cancer research, agriculture & animal research, microbiology & infectious disease research, genetic diseases research, cell & molecular biology research, other application, clinical application, oncology, reproductive health, infectious disease, genetic disorder, other clinical application, end user, pharmaceutical & biotechnology company, hospitals & diagnostic laboratory, academic institutes & research center, other end user.
Key factors driving the growth of this market include the rise in cancer incidence, the increasing application of NGS in cancer treatment and research, and technological advancements in NGS. Furthermore, the rising adoption of genomic data management solutions and collaborations between vendors to develop library preparation protocols are expected to create market growth opportunities.
Report infographic
-Market.webp)
Market dynamics
4 factors across 3 forcesRising Cancer Prevalence & Increasing Application of NGS in Cancer Treatment
Cancer is a leading cause of death and a significant barrier to improving life expectancy in Saudi Arabia. Furthermore, according to GLOBOCAN, cancer incidence in Saudi Arabia is projected to reach 39,900 cases by 2030, an increase from 28,113 cases in 2022. Similarly, cancer-related mortalities are expected to increase from 13,400 in 2022 to 42,100 in 2045. This rising prevalence is anticipated to drive the adoption of NGS in clinical settings. NGS has significantly advanced researchers' understanding of cancer biology by revealing genetic heterogeneity even among cancer types previously thought to be identical. The identification of unique molecular signatures is facilitating the development of potential cancer treatments and driving the demand for NGS in cancer research. The applications of NGS in oncology research include basic drug discovery, translational research, patient testing, and clinical trials. Specifically, NGS is used for diagnostic and prognostic studies, monitoring drug resistance, biomarker identification, therapy selection, and tumor classification.
Increasing Use of NGS in Clinical Applications
NGS technology has revolutionized genetic disease diagnostics with rapid, high-throughput, and cost-effective approaches. NGS technology can simultaneously analyze hundreds of genes, the whole exome, and even the whole genome, enabling researchers to gain a deeper understanding of the genetic heterogeneity of rare diseases. NGS has great potential to enhance cancer diagnosis and care. Using NGS technology, various genomic aberrations, such as common and rare variants, structural variations (e.g., insertions and deletions), copy-number variations, and fusion transcripts, can be screened simultaneously.
NGS has gained significance in clinical practices for oncology, reproductive health, Mendelian disorders, complex diseases, and infectious diseases. In the coming years, NGS is expected to diversify in other clinical areas, with a considerable reduction in sequencing costs. The technology is expected to show substantial penetration in applications such as liquid biopsies for the early detection and monitoring of cancer and reproductive health applications. New biomarkers and actionable mutations are being identified by researchers, which are consequently expected to increase the applications and usage of NGS technology, creating growth opportunities for the players operating in the NGS market.
Table of contents
10 chapters · 102 sections · 183 pages · click to expandSegmental analysis
| Segment | Largest share (2024) | Fastest growth (2024–2031) |
|---|---|---|
| By Offering | Consumables | — |
| By Sequencing Type | Targeted Genome Sequencing | — |
| By Application | Research Applications | — |
By Offering
- The Consumables Segment to Dominate the Market
- The consumables segment is expected to account for the largest share of 62.6% of the Saudi Arabia NGS market.
- This segment is projected to reach $31.8 million by 2031 from an estimated $16.0 million in 2024, at a CAGR of 10.3% during the forecast period.
- Ongoing advancements in reagents, kits, and target enrichment protocols, coupled with the high adoption of sequencing in healthcare facilities, are driving the demand for consumables used in NGS.
- The frequent use of these consumables, coupled with a growing demand for NGS-based diagnostic tests and applications in oncology, reproductive health, and drug discovery, contribute to the significant share of this market segment.
By Sequencing Type
- The targeted genome sequencing segment is expected to account for the largest share of the Saudi Arabia NGS market.
- This segment's significant market share is attributed to the advantages of targeted genome sequencing, such as low cost, quick results, and straightforward data analysis for specific areas of interest.
- These benefits have led to its widespread adoption in diagnostic applications.
- Targeted sequencing is useful for identifying somatic mutations in complex samples such as cancerous tumors mixed with germline DNA, hence used in investigating the genetic causes of cancer and other disorders.
- Thus, the rising use of targeted genome sequencing in the diagnosis is further contributing to the significant market share of this segment.
By Application
- The Research Applications Segment to Dominate the Market
- The research & other applications segment is expected to account for the largest share of 56.9% of the Saudi Arabia NGS market.
- This segment is projected to reach $29.3 million by 2031 from an estimated $ 14.5 million in 2024, at a CAGR of 10.6% during the forecast period.
- The segment's significant market share is due to the rapid adoption of NGS among academic and research institutions, the increasing demand for personalized medicine, and heightened investments by pharmaceutical and biotechnology companies in drug discovery.
- Additionally, the expanding applications of NGS in oncology, agriculture, and other research areas, along with the advantages of genetic research utilizing NGS technology and the rising incidence of cancer, are contributing to the segment’s significant market share.
Competitive landscape
- August 2024
Illumina, Inc. (U.S.) introduced a new oncology menu for customers using the NovaSeq X Series. This includes the launch of a high-throughput version of TruSight Oncology 500 (TSO 500 HT) and the latest iteration of the distributed liquid biopsy research assay, TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2).
- June 2024
Pacific Biosciences of California Inc. (U.S.), in collaboration with the International Consortium for Long-Read Sequencing (CoLoRS), launched a free HiFi long-read variant frequency database. This initiative is designed to assist rare disease researchers by offering access to genetic variants that are not detectable with the short-read sequencing method.
- June 2024
QIAGEN N.V. (Netherlands) launched an updated version of its clinical decision support software, QIAGEN Clinical Insight Interpret (QCI Interpret). This new version improves scalability and performance, specifically designed to meet the needs of high-throughput NGS laboratories.
- July 2023
Thermo Fisher Scientific Inc. (U.S.) launched two new next-generation sequencing-based products, the Ion ReproSeq PGT-A Kit and the Ion AmpliSeq Polyploidy Kit. Both are designed for reproductive health assays and are compatible with the Ion Torrent Genexus Integrated Sequencer.
- Illumina, Inc. (U.S.)
- Thermo Fisher Scientific Inc. (U.S.)
- F. Hoffmann-La Roche Ltd. · Switzerland
- Revvity, Inc. (U.S.)
- QIAGEN N.V. · Netherlands
- Agilent Technologies, Inc. (U.S.)
- Pacific Biosciences of California, Inc. (U.S.)
- Danaher Corporation (U.S.)
- Oxford Nanopore Technologies Plc. (U.K.)
- Beijing Genomics Institute (BGI) · China
- Bio-Rad Laboratories, Inc. (U.S.)
- 10x Genomics, Inc. (U.S.)
Frequently asked questions
Next-generation sequencing (NGS) is a method used to determine the nucleotide sequence of DNA or RNA. By providing a detailed nucleotide sequence, NGS offers the most comprehensive understanding of a gene or genome. This sequence serves as a blueprint, containing critical information for constructing an organism, and is essential for a complete understanding of genetic function and evolution.
This study provides valuable insights, market sizes, and forecasts in terms of value by offering, sequencing type, application, and end user.
Cite this report
Meticulous Research. (2024). Saudi Arabia Next Generation Sequencing (NGS) Market - Opportunity Analysis and Industry Forecast (2024-2031) (Report No. MRHC - 1041319). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/saudi-arabia-ngs-market-6002